Algeta to evaluate novel Targeted Thorium Conjugate (TTC) based on Avipep's Avibody platform

Algeta to evaluate novel Targeted Thorium Conjugate (TTC) based on Avipep's 
Avibody platform 
OSLO, NORWAY -- (Marketwired) -- 06/11/13 -- Algeta ASA (OSE: ALGETA)
announces a collaboration
with Australian biotechnology company
Avipep Pty Ltd to evaluate a novel Targeted Thorium Conjugate (TTC)
based on combining Algeta's proprietary thorium-227
alpha-pharmaceutical payload with an Avibody(TM) from Avipep
that
targets a number of different solid tumor types. 
Under the terms of the agreement, Avipep will provide access to a
proprietary
Avibody, a next-generation antibody fragment, and Algeta
will provide access to chelation and conjugation technologies, as
well as to its alpha particle-emitting payload thorium-227. Both
companies will contribute financially to the collaboration, which is
expected to last for up to one year initially with the
option for
further cooperation thereafter. No further terms have been disclosed. 
Thomas Ramdahl, Executive Vice President and Chief Technology Officer
at Algeta,
said:  "This TTC  evaluation agreement  is a  further step 
towards our goal of building an attractive pipeline of thorium-based
alpha pharmaceuticals. Avivep's
Avibody  has shown excellent tumor
localizing properties in model systems and we hope  that when armed
with our  highly potent thorium-227 payload this novel TTC will offer
maximum therapeutic benefit." 
About the Algeta TTC Platform 
Algeta is evaluating the potential utility of alpha-particle emitting
elements
in the treatment of cancer. Previous studies[i] have
indicated that such elements may have value in treating cancers by
causing double-strand DNA breaks
that trigger cell death, and have
also shown that the effects of alpha-emission are highly localized as
a result of the very short range of the alpha particle (2-10 cell
diameters), potentially minimizing off-target effects. Thorium-227 is
one alpha-particle emitting element (radionuclide) that has been
selected by Algeta for further investigation. By linking thorium-227
to cancer-targeting molecules such as monoclonal antibodies, Algeta
believes it may be possible to develop a pipeline of targeted
alpha-pharmaceuticals, termed Targeted Thorium
Conjugates, or TTCs.
Algeta intends to evaluate TTCs in a broad range of cancer
types to
determine whether the TTC platform could offer advantages over
naked
(un-armed) antibodies or antibody-drug conjugate technologies
that use cytotoxic
drugs (rather than alpha-emitting elements) as
payloads. Such advantages may
include increased potency, a more
localized tumoricidal effect and the potential
to address drug
resistance by virtue of the physical action of the alpha particles. 
For more information about Algeta's technology, please visit www.algeta.com. 
About Algeta 
Algeta  is a company focused on developing novel targeted therapies
for patients
with   cancer  based  on  its  alpha-pharmaceutical 
platform.  The Company  is headquartered in Oslo, Norway, and has a
US subsidiary, Algeta US, LLC, based in Cambridge,  MA performing
commercial  marketing operations in  the US. Algeta is listed  on the
Oslo Stock Exchange (Ticker: ALGETA). For more information
please
visit www.algeta.com. 
About Avipep Pty Ltd 
Avipep  is  a  privately  owned  biotechnology  company  developing
ADCs for the treatment  of cancer.  Avipep's proprietary  Avibody(TM)
products are engineered
antibody  related  proteins  that  can 
deliver  either  cancer-killing drugs or cancer-imaging  agents 
directly  and  specifically  to  tumours. Antibodies are natural 
proteins in the  body's immune system  that can target  cancer cells
by binding  to specific molecules on  the cancer-cell surface.
Avibody(TM) products
leverage the targeting capacity of natural
antibodies but are tuned for improved
tumour targeting and in-vivo
performance. To date the Company has generated pre-clinical  animal
results that  suggest the exciting  potential for the approach.
For
further information about Avipep, visit its website at
www.avipep.com.au. 
Forward-looking Statements 
This  news release contains certain forward-looking statements that
are based on uncertainty,  as they  relate to  events and  depend on 
circumstances that will
occur in the future and which, by their
nature, may have an impact on results of operations   and   the 
financial  condition  of  Algeta.  Such forward-looking statements 
reflect our current views and are based on the information currently
available to Algeta. Algeta cannot give any assurance as to whether
such forward
looking  statements will prove  to be correct.  These
forward looking statements
include statements regarding future
development activities generally and our TTC program  in particular. 
There are  a number of factors  that could cause actual
results and
developments to differ materially from those expressed or implied by
these  forward-looking statements.  These factors  include, among 
other things,
risks  or uncertainties associated  with the success  of
future clinical trials,
collaborations  with other companies in  the
development of targeting molecules,
general  economic and business
conditions and difficulties of obtaining relevant
governmental 
approvals for new products, and  the other risks and
uncertainties
described in our annual report. 
[i] Hall (1994) Radiobiology for the Radiologist (Lippincott,
Philadelphia) 
Press release: http://hugin.info/134655/R/1708266/565961.pdf 
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants
that: 
(i) the releases contained herein are protected by copyright and    
other applicable laws; and 
(ii) they are solely responsible for the content, accuracy and     
originality of the information contained therein. 
Source: Algeta ASA via Thomson Reuters ONE 
[HUG#1708266] 
For further information, please contact: 
Mike Booth / Renate Birkeli
+47 23 00 67 32
Communications & Corporate Affairs
ir@algeta.com 
Media enquiries:
Mark Swallow
+44 207 638 9571
Citigate Dewe Rogerson
mark.swallow@citigatedr.co.uk 
Knut Ekern
+47 22 04 82 00
Gambit Hill & Knowlton
knut.ekern@hkstrategies.com 
Kari Watson
+1 781 235 3060
MacDougall Biomedical Communications
kwatson@macbiocom.com 
US investor enquiries: 
Tricia Swanson
+1 646 378 2953
The Trout Group
tswanson@troutgroup.com
 
 
Press spacebar to pause and continue. Press esc to stop.